InsiderTrades.com logo
Michael W. Dunne net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Dunne Biography and Net Worth

Director of Iterum Therapeutics

Dr. Dunne has over 30 years of experience in the life science industry. From 2020 to January 2025, Dr. Dunne served as the chief medical officer at the Gates Medical Research Institute.  Previously, Dr. Dunne served as the chief scientific officer of Iterum Therapeutics. Before Iterum, Dr. Dunne was the Chief Medical Officer of Durata Therapeutics, Inc. from 2009 until its acquisition by Actavis plc in 2014 and remained in a leadership role as part of the Actavis integration efforts to ensure successful transition of all priority development activities until 2015. From 1992 to 2009, Dr. Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., including as the Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne also served as a member of the board of directors of Aviragen Therapeutics, Inc, a biotechnology company from 2015 to 2018. Dr. Dunne holds a BA in Economics from Northwestern University and an MD from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.

What is Michael W. Dunne's net worth?

The estimated net worth of Michael W. Dunne is at least $7.23 thousand as of November 18th, 2025. Dr. Dunne owns 241,001 shares of Iterum Therapeutics stock worth more than $7,230 as of October 12th. This net worth approximation does not reflect any other investments that Dr. Dunne may own. Learn More about Michael W. Dunne's net worth.

How do I contact Michael W. Dunne?

The corporate mailing address for Dr. Dunne and other Iterum Therapeutics executives is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. Iterum Therapeutics can also be reached via phone at (531) 669-4820 and via email at [email protected]. Learn More on Michael W. Dunne's contact information.

Has Michael W. Dunne been buying or selling shares of Iterum Therapeutics?

Michael W. Dunne has not been actively trading shares of Iterum Therapeutics in the last ninety days. Most recently, on Tuesday, November 18th, Michael W. Dunne bought 6,000 shares of Iterum Therapeutics stock. The stock was acquired at an average cost of $0.37 per share, with a total value of $2,220.00. Following the completion of the transaction, the director now directly owns 241,001 shares of the company's stock, valued at $89,170.37. Learn More on Michael W. Dunne's trading history.

Are insiders buying or selling shares of Iterum Therapeutics?

In the last year, Iterum Therapeutics insiders bought shares 1 times. They purchased a total of 6,000 shares worth more than $2,220.00. The most recent insider tranaction occured on November, 18th when Director Michael W. Dunne bought 6,000 shares worth more than $2,220.00. Insiders at Iterum Therapeutics own 2.0% of the company. Learn More about insider trades at Iterum Therapeutics.

Information on this page was last updated on 11/18/2025.

Michael W. Dunne Insider Trading History at Iterum Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2025Buy6,000$0.37$2,220.00241,001View SEC Filing Icon  
8/8/2025Buy15,000$0.72$10,800.00235,001View SEC Filing Icon  
12/22/2023Buy25,000$1.40$35,000.00113,754View SEC Filing Icon  
11/22/2023Buy20,000$2.03$40,600.0078,754View SEC Filing Icon  
9/7/2022Buy10,000$2.22$22,200.0035,576View SEC Filing Icon  
1/26/2021Sell33,143$1.73$57,337.39289,498View SEC Filing Icon  
9/4/2018Buy500$10.00$5,000.00View SEC Filing Icon  
8/27/2018Buy1,000$10.00$10,000.00View SEC Filing Icon  
5/30/2018Buy2,000$13.00$26,000.00View SEC Filing Icon  
See Full Table

Michael W. Dunne Buying and Selling Activity at Iterum Therapeutics

This chart shows Michael W. Dunne's buying and selling at Iterum Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Iterum Therapeutics Company Overview

Iterum Therapeutics logo
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.03
Low: $0.03
High: $0.03

2 Week Range

Now: $0.03
Low: $0.03
High: $1.42

Volume

N/A

Average Volume

4,853,695 shs

Market Capitalization

$1.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.96